Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) and Structure Therapeutics (NASDAQ:GPCR – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.
Volatility & Risk
Dermata Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.5, indicating that its stock price is 250% less volatile than the S&P 500.
Institutional & Insider Ownership
8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 21.9% of Dermata Therapeutics shares are held by insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dermata Therapeutics | N/A | N/A | -$7.56 million | ($5.31) | -0.25 |
| Structure Therapeutics | N/A | N/A | -$141.20 million | ($0.87) | -58.20 |
Structure Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Dermata Therapeutics and Structure Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dermata Therapeutics | N/A | -127.91% | -105.05% |
| Structure Therapeutics | N/A | -24.91% | -23.67% |
Analyst Ratings
This is a summary of recent recommendations for Dermata Therapeutics and Structure Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dermata Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Structure Therapeutics | 2 | 1 | 12 | 3 | 2.89 |
Dermata Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 658.15%. Structure Therapeutics has a consensus price target of $110.55, suggesting a potential upside of 118.34%. Given Dermata Therapeutics’ higher probable upside, equities analysts plainly believe Dermata Therapeutics is more favorable than Structure Therapeutics.
Summary
Structure Therapeutics beats Dermata Therapeutics on 7 of the 12 factors compared between the two stocks.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
About Structure Therapeutics
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
